{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:10:01Z","timestamp":1792815001431,"version":"4.5.0"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Zanubrutinib (BGB-3111, Brukinsa<jats:sup>\u00ae<\/jats:sup>, BeiGene) is a next-generation irreversible inhibitor of Bruton\u2019s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies. It was designed to minimize off-target inhibition of TEC- and EGFR-family kinases. Zanubrutinib is more selective than ibrutinib for BTK versus EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK, BLK and TEC. In addition, compared to ibrutinib, zanubrutinib has improved oral absorption and better target occupancy. Zanubrutinib demonstrated a lower incidence of off-target toxicities and reduced severity than ibrutinib. Moreover, zanubrutinib is similar to acalabrutinib, with less activity against TEC and ITK. The preliminary phase 1 results suggest that zanubrutinib has clinical activity and the drug is well tolerated in patients with B-cell lymphoid malignancies. Recent clinical trials have found it to demonstrate excellent efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM) and mantle cell lymphoma (MCL). In recent phase 3 studies, zanubrutinib was compared with ibrutinib in patients with relapsed\/refractory (R\/R) MW and RR CLL. In both trials, zanubrutinib was found to demonstrate clinically meaningful advantages in safety and tolerability over ibrutinib; in particular, it was associated with a lower risk of atrial fibrillation\/flutter and major bleeding events. In the recent SEQUOIA study, comparing zanubrutinib with bendamustine and rituximab (BR) in patients with previously untreated CLL, zanubrutinib significantly improved progression-free survival versus BR, with an acceptable safety profile consistent with previous studies. Zanubrutinib also demonstrated good activity and tolerability in patients with R\/R MCL, marginal zone lymphoma and follicular lymphoma. Trials examining the efficacy and safety of the combination of zanubrutinib with obinutuzumab venetoclax and other drugs are ongoing. This review summarizes the clinical efficacy and safety of zanubrutinib in lymphoid malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2023.1130595","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T06:34:23Z","timestamp":1679553263000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions"],"prefix":"10.3389","volume":"13","author":[{"given":"Anna","family":"Wolska-Washer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of b-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active b-cell-receptor signalling in diffuse large b-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/J.IT.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703\/75971\/AM\/TREATMENT-OF-PATIENTS-WITH-RELAPSED-OR-REFRACTORY","article-title":"Treatment of patients with relapsed or refractory mantle\u2013cell lymphoma with zanubrutinib, a selective inhibitor of bruton\u2019s tyrosine kinase","volume":"26","author":"Song","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2021-144336","article-title":"Zanubrutinib in combination with venetoclax for patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): Early results from arm d of the SEQUOIA (BGB-3111-304) trial","volume":"138","author":"Tedeschi","year":"2021","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020002183","article-title":"Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7510","article-title":"Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial","volume":"40","author":"Zinzani","year":"2022","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12061396","article-title":"Mechanisms of b cell receptor activation and responses to b cell receptor inhibitors in b cell malignancies","volume":"12","author":"Efremov","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton\u2019s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for b-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830231210","article-title":"The bruton\u2019s tyrosine kinase gene is expressed throughout b cell differentiation, from early precursor b cell stages preceding immunoglobulin gene rearrangement up to mature b cell stages","volume":"23","author":"de Weers","year":"1993","journal-title":"Eur J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030771","article-title":"The role of bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: current status and future directions","volume":"14","author":"Robak","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1384814","article-title":"Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia","volume":"26","author":"Robak","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2013-07-515361","article-title":"Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022369","article-title":"Distinct effects of ibrutinib and acalabrutinib on mouse atrial and sinoatrial node electrophysiology and arrhythmogenesis","volume":"10","author":"Tuomi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/EJH.13020","article-title":"Systematic review of infectious events with the bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur J Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/JTH.13651","article-title":"Ibrutinib-associated bleeding; pathogenesis, management, and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Hemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/S40257-020-00535-X","article-title":"Dermatological toxicities of bruton\u2019s tyrosine kinase inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/JHA2.269","article-title":"Comparison of inhibitory effects of irreversible and reversible btk inhibitors on platelet function","volume":"2","author":"Tullemans","year":"2021","journal-title":"Eur J Hematol"},{"key":"B25","unstructured":"BRUKINSA\u00ae (zanubrutinib) BTK inhibitor official BeiGene website"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/S40265-019-01252-4","article-title":"Zanubrutinib: First approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JMEDCHEM.9B00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in b-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-162135","article-title":"Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed\/refractory MCL: an updated pooled analysis","volume":"140","author":"Song","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2217\/FON-2020-0794","article-title":"A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma","volume":"17","author":"Dreyling","year":"2021","journal-title":"Future Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/BLOOD-2022-163018","article-title":"Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized triangle trial by the European MCL network","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2021-151831","article-title":"Preliminary safety and efficacy from a multicenter, investigator-initiated phase ii study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-166237","article-title":"Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course r-dhaox shows potent efficacy in patients with mantle cell lymphoma (MCL) - preliminary results of phase II CHESS clinical trial","volume":"140","author":"Cai","year":"2022","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the surveillance, epidemiology and end results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000634","article-title":"EHA endorsement of ESMO clinical practice guidelines for diagnosis, treatment, and follow-up for Waldenstrom's macroglobulinemia","volume":"5","author":"Staber","year":"2021","journal-title":"Hemasphere"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/J.LEUKRES.2016.10.008","article-title":"Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"51","author":"Burnworth","year":"2016","journal-title":"Leuk Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstrom's macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-agent ibrutinib for rituximab-refractory waldenstr\u00f6m macroglobulinemia: Final analysis of the substudy of the phase III innovateTM trial","volume":"27","author":"Trotman","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020006449","article-title":"Zanubrutinib for the treatment of patients with waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020008197","article-title":"The race to stymie BTK: zanu zings","volume":"136","author":"Kapoor","year":"2020","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.13278","article-title":"The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 wild-type and CXCR4 WHIM mutated waldenstrom macroglobulinaemia cells","volume":"170","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-162338","article-title":"Zanubrutinib plus ixazomib and dexamethasone for newly diagnosed symptomatic waldenstr\u00f6m macroglobulinemia: A prospective, phase II study","volume":"140","author":"Yu","year":"2022","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/BJH.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21037\/AOL-20-20","article-title":"Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond","volume":"4","author":"Lue","year":"2020","journal-title":"Ann Lymphoma."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1941864","article-title":"Evaluating ibrutinib for the treatment of relapsed\/refractory marginal zone lymphoma","volume":"22","author":"Cavalloni","year":"2021","journal-title":"Expert Opin Pharmacother."},{"key":"B56","unstructured":"StewardJ\n          Brukinsa (zanubrutinib) FDA approval history - drugs.com"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips","year":"2022","journal-title":"Blood Adv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1704\/673971\/AM\/THE-MAGNOLIA-TRIAL-ZANUBRUTINIB-A-NEXT-GENERATION","article-title":"The MAGNOLIA trial: Zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-163371","article-title":"Long-term efficacy and safety of zanubrutinib in patients with relapsed\/refractory (R\/R) marginal zone lymphoma (MZL): Final analysis of the magnolia (BGB-3111-214) trial","volume":"140","author":"Opat","year":"2022","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/S13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/BJH.18162","article-title":"A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory b-cell malignancies","volume":"198","author":"Song","year":"2022","journal-title":"Br J Haematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/S12325-022-02238-7","article-title":"Zanubrutinib monotherapy for na\u00efve and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: a pooled analysis of three studies","volume":"39","author":"Xu","year":"2022","journal-title":"Adv Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845532.14560.fe","article-title":"Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-na\u00efve (TN) CLL\/SLL","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-019-0602-X","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1159\/000528019","article-title":"Ibrutinib and Bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias\/sudden cardiac death","author":"Boriani","year":"2022","journal-title":"Chemotherapy"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk Lymphoma."},{"key":"B67","volume-title":"Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed\/refractory (RR) CLL\/SLL: results from the randomized phase 3 ALPINE trial","author":"Hillmen","year":"2022"},{"key":"B68","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/J.1365-2141.2005.05508.X","article-title":"A population-based study of severity of comorbidity among patients with non-hodgkin\u2019s lymphoma: prognostic impact independent of international prognostic index","volume":"129","author":"Janssen-Heijnen","year":"2005","journal-title":"Br J Haematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large b-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.21873\/ANTICANRES.15384","article-title":"Clinicopathologic and prognostic significance of bruton\u2019s tyrosine kinase expression in diffuse large b-cell lymphoma","volume":"41","author":"Han","year":"2021","journal-title":"Anticancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00123-4","article-title":"Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large b-cell lymphoma: a phase 2, single-arm study","volume":"3","author":"Xu","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020003698","article-title":"Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large b-cell lymphoma","volume":"6","author":"Yang","year":"2022","journal-title":"Blood Adv"},{"key":"B77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/S40164-022-00314-W","article-title":"Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large b-cell lymphoma: a real-world analysis of single center","volume":"11","author":"Zhu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-164486","article-title":"Gentle initiation\u201d rituximab, lenalidomide and zanubrutinib chemo-free regimen followed by immunochemotherapy for elderly\/frail patients with newly diagnosed diffuse large b-cell lymphoma: an investigator initiated, single arm, phase 2 trial","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center b-cell diffuse large b-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-168859","article-title":"Zanubrutinib plus RCHOP(ZR-CHOP) regimen achieves high complete response rate in the treatment of newly-diagnosed double-expression diffuse large b cell lymphoma","volume":"140","author":"He","year":"2022","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-155979","article-title":"Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed\/refractory diffuse large b-cell lymphoma","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood-2022-158723","article-title":"The ZR2-MiniCHOP Study:zanubrutinib, lenalidomide, rituximab, cyclophosphamide, vincristine, epirubicin and prednisone in elderly patients with previously untreated diffuse large b-cell lymphoma","volume":"140","author":"Sun","year":"2022","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"20406207221141510","DOI":"10.1177\/20406207221141511","article-title":"The role of CAR-T cell therapy as second line in diffuse large b-cell lymphoma","volume":"13","author":"Albanyan","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1596793","article-title":"Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large b-cell lymphoma","volume":"12","author":"Dahi","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.894787","article-title":"Case report: dual inhibition of HDAC and BTK for diffuse large b-cell lymphoma after failure to CD19-targeted CAR-T therapy","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLML.2022.08.006","article-title":"The prognostic significance of CD79B mutation in diffuse large b-cell lymphoma: a meta-analysis and systematic literature review","volume":"22","author":"Xu","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-165944","article-title":"Preliminary results of a phase ii study of zanubrutinib combined with immunochemotherapy in patients with CD79A\/CD79B-mutant diffuse large b-cell lymphoma","volume":"140","author":"Yao","year":"2022","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S267258","article-title":"Chemotherapy-free management of follicular and marginal zone lymphoma","volume":"13","author":"Ollila","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2022-157563","article-title":"Safety and efficacy of the PI3K\u03b4 inhibitor zandelisib in combination with the BTK inhibitor zanubrutinib in patients with Relapsed\/Refractory (R\/R) follicular lymphoma (FL) or mantle cell lymphoma (MCL)","volume":"140","author":"Soumerai","year":"2022","journal-title":"Blood"},{"key":"B92","unstructured":"Company statements. Gilead statement on zydelig\u00ae U.S. indication for follicular lymphoma and small lymphocytic leukemia"},{"key":"B93","unstructured":"MEI and kyowa kirin to discontinue developing zandelisib outside Japan"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1130595\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T06:34:31Z","timestamp":1679553271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1130595\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":93,"alternative-id":["10.3389\/fonc.2023.1130595"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1130595","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"article-number":"1130595"}}